PhRMA: Nearly 300 preventive medicines for heart disease, stroke in development
WASHINGTON — A new report developed by the Pharmaceutical Research and Manufacturers of America revealed that nearly 300 heart disease and stroke medicines are in development.
PhRMA said that while 299 medicines are in development by the nation’s biopharmaceutical companies, there is a growing need for such drugs; African-Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.
“Medicines developed for cardiovascular health over the last three decades are in large measure responsible for preventing more than [one] million American deaths a year,” PhRMA president and CEO John Castellani said. “We have made and continue to make great progress in treating cardiovascular disease, but we also urge all Americans to take every precaution available to prevent it.”
CPF adds member to board of directors
STOUGHTON, Wis. — The Community Pharmacy Foundation has appointed a new member to its board.
Randall Myers, a Carey, Ohio-based pharmacist who owns Harry’s Pharmacy, joined CPF, which provides support funding for projects associated with community pharmacies in which pharmacists desire to advance their scope of services to assist patients with their disease state management and medication therapy management needs.
Myers is a 1982 graduate of Raabe College of Pharmacy at Ohio Northern University. He has received numerous professional recognitions, such as the AmerisourceBergen Good Neighbor Pharmacy Pharmacist of the Year, the Distinguished Achievement Award in Community/Ambulatory Practice from the American Pharmacists Association in 2007 and the National Community Pharmacists Association Prescription Drug Safety Award the same year.
Dr. Reddy’s gets OK to market generic allergy drug
HYDERABAD, India — A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.
Dr. Reddy’s said the U.S. District Court of New Jersey had filed a stipulation and order lifting the earlier injunction against the drug maker regarding the selling of a version of fexofenadine hydrochloride and pseudoephedrine hydrochloride tablets in the 180-mg/240-mg strength. The drug is a generic version of Sanofi-Aventis’ and Albany Molecular Research’s Allegra-D 24.
Sanofi and Albany Molecular Research had filed suit against Dr. Reddy’s, alleging patent infringement. In June 2010, the court granted the two companies an injunction preventing Dr. Reddy’s from selling its version of the drug.